Loading...
  •  

Cesca Therapeutics Inc. Announces Two Abstracts Accepted for Poster Presentation at the International Society for Cellular Therapy (ISCT) 2018 Annual Meeting

Cesca Therapeutics Inc. Announces Two Abstracts Accepted for Poster Presentation at the International Society for Cellular Therapy (ISCT) 2018 Annual Meeting

March 28, 2018

RANCHO CORDOVA, Calif., March 28, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) today announced that two late-breaking abstracts involving the use of Cesca’s X-Series™ technologies for cell processing have been accepted for presentation as posters at the ISCT 2018 Annual Meeting, which is being held May 2-5, 2018 at the Palais des Congrès de Montréal in Montreal, Québec.  Details of the poster presentations are as follows:

Abstract 2963114: Novel buoyancy based cell selection: X-BACS™ Technology
Poster number/abstract ID number: 380
Poster Session 2: May 4, 2018, 5:00-6:30PM

Abstract 2963911: Quick and easy method for removal of DMSO from thawed cellular products
Poster number/abstract ID number: 381
Poster Session 2: May 4, 2018, 5:00-6:30PM

About the International Society for Cellular Therapy (ISCT) Annual Meeting
ISCT is a global society of clinicians, regulators, technologists, and industry partners with a shared vision to translate cellular therapy into safe and effective therapies to improve patients' lives. ISCT members gain access to an influential global community of peers, experts, and organizations invested in cell therapy. ISCT offers a unique collaboration between academia, regulatory bodies, and industry partners in cell therapy translation.

About Cesca Therapeutics Inc.        
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress™ platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.

Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
ir@cescatherapeutics.com

Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
pschwartz@rxir.com

Primary Logo

Source: Cesca Therapeutics Inc.